Pfizer's Q1 net jumps 14 pct., sales just miss expectations

May 1, 2018 by Linda A. Johnson
Pfizer's Q1 net jumps 14 pct., sales just miss expectations
This Dec. 4, 2017, file photo shows a tablet of Pfizer's Viagra, left, and the company's generic version, sildenafil citrate, at Pfizer Inc., headquarters in New York. Pfizer Inc. reports earnings Tuesday, May 1, 2018. (AP Photo/Richard Drew, File)

Pfizer posted slightly higher sales and a 14 percent jump in profit in the first quarter, thanks to lower restructuring costs and a much-lower tax rate, but its revenue still missed Wall Street expectations.

The maker of pain medicine Lyrica and the blockbuster Prevnar 13 vaccine against pneumococcal infections said Tuesday that net income was $3.56 billion, or 59 cents per . That was up from $3.12 billion, or 51 cents per share, a year earlier, when there were more shares being publicly traded.

The New York company's earnings, adjusted for non-recurring costs, came to 77 cents per share. That was 3 cents better than industry analysts had expected, according to a survey by Zacks Investment Research.

Revenue totaled $12.91 billion, up 1 percent but short of the $13.09 billion analysts had projected.

"Our first-quarter 2018 financial results were solid, driven by continued strength from our anchor brands ," Chief Executive Ian Read said in a statement, citing breast cancer Ibrance, advanced blood thinner Eliquis and rheumatoid arthritis pill Xeljanz.

Sales in the company's Innovative Health business, which sells those medicines and other patented drugs, rose 6 percent to $7.83 billion, led by jumps of 35 percent or more for Eliquis and Ibrance.

The Essential Health Division, which sells Viagra, cholesterol pill Lipitor and other older, off-patent drugs, saw sales slide 5 percent to $5.08 billion. The consumer health division, which Pfizer has been considering selling, posted a 7 percent sales increase, to $905 million.

"Our pipeline today, with a range of targeted compounds, biologics and vaccines, is as deep and focused as it has ever been," Read said.

Pfizer noted that during the quarter it used part of its benefit from the December federal tax cut to pay shareholders $2 billion in dividends and to repurchase $6.1 billion worth of its shares.

The drug giant reaffirmed its 2018 financial forecast, saying it expects full-year adjusted earnings between $2.90 and $3 per share, with revenue in the range of $53.5 billion to $55.5 billion.

In premarket trading, Pfizer shares fell 31 cents at $36.30.

Explore further: Key drug sales push Pfizer profit up 50 percent

Related Stories

Key drug sales push Pfizer profit up 50 percent

August 1, 2017
Rising sales of most key drugs, lower one-time charges and reduced manufacturing costs helped drive Pfizer's second-quarter profit up 50 percent.

Pfizer Q4 net jumps on sale of nutrition business

January 29, 2013
Pfizer Inc.'s fourth-quarter profit more than quadrupled, despite competition from generic drugs hurting sales of Lipitor and other medicines, because of a $4.8 billion gain from selling its nutrition business. The drugmaker's ...

Pfizer 1Q profit drops 15 pct due to lower sales (Update)

May 5, 2014
Despite sharply lower expenses and taxes, Pfizer Inc.'s first-quarter profit dropped 15 percent, due to cheaper generic competition for multiple medicines and some promotion partnerships with other drugmakers ending.

Pfizer's 4Q net plunges on charges, sales decline

January 28, 2014
Drugmaker Pfizer said Tuesday that fourth-quarter profit plunged 59 percent because of discontinued operations, restructuring and other charges, and generic competition continuing to siphon off revenue from former blockbuster ...

Pfizer net down on lower sales, higher research, legal costs

January 27, 2015
Pfizer Inc.'s fourth-quarter profit fell by half as worsening generic competition and unfavorable currency rates reduced sales, and higher research and legal costs also reduced the bottom line.

Pfizer beats Street 2Q forecasts despite big drop in profit

August 2, 2016
Rising sales of Pfizer Inc.'s key new medicines and prospects more drugs will be approved over the next couple years have analysts speculating the biggest U.S. drugmaker won't break up after all.

Recommended for you

Why men say they've had more lifetime sexual partners than women

July 25, 2018
The disparity between the number of sexual partners reported by men and women can largely be explained by a tendency among men to report extreme numbers of partners, and to estimate rather than count their lifetime total, ...

Censors jump into action as China's latest vaccine scandal ignites

July 22, 2018
Chinese censors on Sunday deleted articles and postings about the vaccine industry as an online outcry over the country's latest vaccine scandal intensified.

Revenge of a forgotten medical 'genius'

June 30, 2018
It's not an uncommon fate for a pioneering scientist: languishing unrecognised in his time before dying in obscurity. But as his 200th birthday approaches, the life-saving work of a Hungarian obstetrician is finally getting ...

Yes, you can put too much chlorine in a pool

June 2, 2018
(HealthDay)—Before you take a dip in the pool this summer, be sure there's not too much chlorine in the water.

Best of Last Year—The top Medical Xpress articles of 2017

December 20, 2017
It was a good year for medical research as a team at the German center for Neurodegenerative Diseases, Magdeburg, found that dancing can reverse the signs of aging in the brain. Any exercise helps, the team found, but dancing ...

Pickled in 'cognac', Chopin's heart gives up its secrets

November 26, 2017
The heart of Frederic Chopin, among the world's most cherished musical virtuosos, may finally have given up the cause of his untimely death.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.